Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and purpose: Inhibitors of histone deacetylase (HDAC) are emerging as a promising class of anti‐cancer drugs, but a generic deregulation of transcription in neoplastic cells cannot fully explain their therapeutic effects. In this study we evaluated alternative molecular mechanisms by which HDAC inhibitors could affect neuroblastoma viability. Experimental approach: Effects of HDAC inhibitors on survival of the I‐type SK‐N‐BE and the N‐type NB SH‐SY5Y neuroblastoma cell lines were assessed by the MTT assay. Molecular pathways leading to this were examined by western blot, confocal microscopy and cytofluorometry. The mRNA levels of apoptotic mediators were assessed semi‐quantitatively by RT‐PCR. Tumour‐suppressor p53 trans activity was assessed in EMSA experiments. HDAC inhibitors were also studied in cells subjected to plasmid‐based p53 interference (p53i). Key results: HDAC inhibitors induced cell death via the mitochondrial pathway of apoptosis with recruitment of Bcl‐2 family members. Bcl‐2 overexpression rendered neuroblastoma cells resistant to HDAC inhibitor treatment. Low concentrations of HDAC inhibitors (0.9 m M) caused a G 2 cell‐cycle arrest and a marked upregulation of the p21/Waf1/Cip1 protein. HDAC inhibitors also activate the p53 protein via hyper‐acetylation and nuclear re‐localization, without affecting its protein expression. Accordingly, HDAC inhibitor‐induced cell‐killing and p21/Waf1/Cip1 upregulation is impaired in p53i‐cells. Conclusions and implications: In neuroblastoma cells, HDAC inhibitors may overcome the resistance to classical chemotherapeutic drugs by restoring the p53 tumour‐repressor function via its hyper‐acetylation and nuclear migration, events usually impaired in such tumours. In neuroblastoma cells, HDAC inhibitors are not able to induce p21/Waf1/Cip1 in the absence of a functional p53. British Journal of Pharmacology (2008) 153, 657–668; doi:10.1038/sj.bjp.0707608; published online 3 December 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of mitochondrial apoptosis-inducing factor
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999) · Nature · doi:10.1038/17135 · Cited by 4,060 · cited 1×
“At the same time, this does not exclude the release of other cell-death effectors, such as apoptosis-inducing factor (Susin et al., 1999) and endonuclease G (Widlak and Garrard, 2005), by mitochondria, as we observed for cytochrome c (Figures 2b and c).”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 2×
“, 2002) depending on the cell type considered, suggesting that HDACs might represent a relevant target for cancer therapy (Marks et al., 2001).”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 4×
“, 2003) but lacks inhibition of HDAC (Phiel et al., 2001).”
BackgroundMethodInfluentialThe p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 2×
“Furthermore, protein acetylation is emerging as a post-transcriptional modification determining the regulation of several signal-transduction pathways (Glozak et al., 2005).”
Background
Cited by
Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0055 · Cited by 248
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Liu, Q., Zhang, B., Wang, Y., Wang, X., & Gou, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114058 · Cited by 49
Metadata
- Authors
- Condorelli, F., Gnemmi, I., Vallario, A., Genazzani, A. A., & Canonico, P. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-02
- Volume
- 153
- Issue
- 4
- Pages
- 657-668
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2164360261
- Cited by
- 121
- References
- 5
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. https://app.cochat.ai/papers/10.1038/sj.bjp.0707608
- The paper
- Condorelli, F., Gnemmi, I., Vallario, A., Genazzani, A. A., & Canonico, P. L. (2008). Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707608
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.